Non-profitUnited Kingdomworldobesity.org
Also known as International Association for the Study of Obesity and IASO.
None yet. When a new project in the record names World Obesity Federation as owner, partner or investor, it shows here.
Phase II starts for a potential first‑in‑class triple GLP‑1/GIP/NPY2 receptor agonist targeting weight, satiety and central hunger signalling; study includes dose finding and safety/efficacy evaluation.
